Lateral Epicondylitis Treatment Market Report 2026

The lateral epicondylitis treatment market size has grown strongly in recent years. It will grow from $2.34 billion in 2025 to $2.46 billion in 2026 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to sports-related injury prevalence, repetitive occupational strain, orthopedic clinic expansion, traditional physiotherapy adoption, NSAID-based pain management.

The lateral epicondylitis treatment market size is expected to see steady growth in the next few years. It will grow to $2.98 billion in 2030 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to minimally invasive treatment adoption, aging workforce population, digital physiotherapy platforms, demand for faster recovery solutions, outpatient surgical advancements. Major trends in the forecast period include growing preference for non-surgical interventions, increased adoption of physical therapy protocols, rising use of image-guided injections, expansion of outpatient orthopedic care, integration of rehabilitation and pain management.

The increase in sports and physical activities is expected to drive growth in the lateral epicondylitis treatment market in the coming years. Sports and physical activities include structured or recreational movements undertaken to improve fitness, maintain health, or engage in competitive or leisure pursuits. Participation in these activities is rising due to greater health awareness, as more individuals prioritize fitness to prevent diseases and enhance mental and physical well-being. Lateral epicondylitis treatments support active individuals by restoring pain-free arm function, enabling movements such as gripping and swinging without discomfort or limitation. For example, according to the Sports and Fitness Industry Association in February 2024, 78.8% of Americans, or 242 million people, participated in at least one physical activity in 2023, a 2.2% increase from 2022. Consequently, the growth in sports and physical activities is fueling the lateral epicondylitis treatment market.

Leading companies in the lateral epicondylitis treatment market are developing innovative solutions, such as plasma therapies, to expand treatment options and provide advanced, non-surgical care for orthopedic conditions. Plasma therapies use components of blood plasma, including antibodies and growth factors, to support healing and treat various medical conditions. For instance, in December 2023, Tree Top Hospital (TTH), a Maldives-based hospital, introduced platelet-rich plasma (PRP) treatments as part of its orthopedic care services. This therapy leverages the body’s natural healing properties to treat conditions such as lateral epicondylitis (tennis elbow), early-stage knee arthritis, and sports-related tendon injuries. By offering PRP therapy, TTH aims to enhance recovery through minimally invasive, evidence-based regenerative solutions that reduce the need for surgical interventions.

In March 2023, TendoNova, a US-based company specializing in lateral epicondylitis treatment, partnered with AcCELLerated Biologics LLC to expand market reach and clinical capabilities. The collaboration integrates micro-invasive tendon treatment technologies with biologic therapies, increasing physician access and improving patient outcomes for chronic tendon disorders. AcCELLerated Biologics LLC is a US-based provider of biologic products for the treatment of lateral epicondylitis.

Major companies operating in the lateral epicondylitis treatment market are Merck & Co. Inc., 3M Company, Mayo Foundation for Medical Education and Research (MFMER), Cleveland Clinic, Chugai Pharmaceutical, Johns Hopkins Medicine, MedStar Health, Cipla Inc., Enovis Corporation, OttoBock HealthCare, Ossur Corporate, Max Healthcare, Seikagaku Corporation, Texas Orthopedic Specialists, Johari Digital, Mediheal Group of Hospitals, Scandinavian Physiotherapy Center, Veritas Health LLC, Folsom Orthopaedics & Sports Medicine, ReLiva Physiotherapy & Rehab, Molecular Pharmacology Limited.

North America was the largest region in the lateral epicondylitis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lateral epicondylitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lateral epicondylitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the lateral epicondylitis treatment market by increasing the cost of medical devices, injectable corticosteroids, orthopedic supports, and surgical instruments. Non-surgical therapies such as injections and orthotic devices are most impacted, particularly in North America and Europe due to reliance on imported medical components. Hospitals, orthopedic clinics, and ambulatory centers face rising treatment costs. Positively, tariffs are encouraging domestic manufacturing of rehabilitation equipment and injectable pharmaceuticals, strengthening local healthcare supply chains.

The lateral epicondylitis treatment market research report is one of a series of new reports that provides lateral epicondylitis treatment market statistics, including lateral epicondylitis treatment industry global market size, regional shares, competitors with a lateral epicondylitis treatment market share, detailed lateral epicondylitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the lateral epicondylitis treatment industry. This lateral epicondylitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lateral epicondylitis treatment encompasses a range of clinical interventions designed to reduce pain, decrease inflammation, and promote recovery in individuals with lateral epicondylitis, a condition caused by overuse or strain of the forearm tendons. The goal is to restore normal arm function, improve mobility and strength, and enable a return to daily or occupational activities without recurring symptoms.

The main types of treatment for lateral epicondylitis include non-surgical and surgical approaches. Non-surgical treatment involves conservative therapies such as physical therapy, bracing, medications, and regenerative techniques like platelet-rich plasma (PRP) to relieve pain, reduce inflammation, and restore function without surgery. These treatments are used across various age groups, including pediatric, adult, and geriatric populations, and in applications such as sports and general activity. End users include hospitals, ambulatory surgical centers, orthopedic clinics, homecare settings, and other healthcare facilities.

The lateral epicondylitis treatment market consists of revenues earned by entities by providing services such as outpatient musculoskeletal physiotherapy sessions, telehealth consultations for elbow pain, occupational therapy programs, post-surgical recovery and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The lateral epicondylitis treatment market also includes sales of platelet-rich plasma (PRP) kits, extracorporeal shock wave therapy (ESWT) devices, ultrasound therapy equipment, elbow support braces with biofeedback sensors, and topical anti-inflammatory gels. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.